CRBU News and Press, Caribou Biosciences Inc. From 07/14/23

2023-07-14 14:12:48 ET Caribou Biosciences is down 23% in Friday trading after announcing following Thursday's closing bell a $125M stock offering and phase 1 data on a non-Hodgkin's lymphoma CAR-T candidate. The offering was upsized to $150M from $125M. It was priced late Thurs...

2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...

2023-07-14 03:31:44 ET Genome-editing biopharmaceutical company Caribou Biosciences ( NASDAQ: CRBU ) has upsized underwritten public offering of 19.23 million shares at a public offering price of $6.50 per share. Gross proceeds from the offering are expected to ...

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a public o...

2023-07-13 16:09:56 ET Genome-editing biopharmaceutical company Caribou Biosciences ( NASDAQ: CRBU ) said on Thursday that it has commenced a $100M underwritten public offering of shares. The company intends to grant the underwriters a 30-day option to purchase up to an a...

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou ...

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is th...

2023-07-13 09:30:00 ET The stock market rewards innovation, especially when it comes to new products and/or services that create or disrupt entire industries. Some of the best-performing stocks in the past two decades have been fueled by advances in cutting-edge areas such as artificial int...

2023-07-06 15:42:08 ET With the uptick of volatility in the stock market today, there’s no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there’s a significant global catalys...

2023-07-06 11:54:56 ET Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the company. The healthcare stock is up more than 3% ...